Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.770
-0.080 (-4.32%)
At close: Mar 9, 2026, 4:00 PM EDT
1.770
0.00 (0.00%)
After-hours: Mar 9, 2026, 5:49 PM EDT

Lineage Cell Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
441405111191199413
Upgrade
Market Cap Growth
236.30%265.38%-41.93%-4.09%-51.84%56.44%
Upgrade
Enterprise Value
38836679151134349
Upgrade
Last Close Price
1.771.670.501.091.172.45
Upgrade
PS Ratio
30.2927.8011.6621.3213.5395.13
Upgrade
PB Ratio
9.669.341.443.082.774.54
Upgrade
P/TBV Ratio
202.52185.895.2330.8412.4511.89
Upgrade
P/FCF Ratio
----307.85-
Upgrade
P/OCF Ratio
----187.79-
Upgrade
EV/Sales Ratio
26.6225.128.3616.889.1180.50
Upgrade
EV/FCF Ratio
----207.31-
Upgrade
Debt / Equity Ratio
0.060.060.030.050.050.03
Upgrade
Debt / FCF Ratio
----6.03-
Upgrade
Net Debt / Equity Ratio
-1.23-1.23-0.59-0.52-0.75-0.61
Upgrade
Net Debt / EBITDA Ratio
2.532.532.171.592.481.15
Upgrade
Net Debt / FCF Ratio
2.752.751.911.11-83.562.32
Upgrade
Asset Turnover
0.130.130.090.080.100.03
Upgrade
Quick Ratio
5.055.053.472.023.072.32
Upgrade
Current Ratio
5.205.203.652.143.162.37
Upgrade
Return on Equity (ROE)
-105.30%-105.30%-26.73%-32.07%-32.37%-46.52%
Upgrade
Return on Assets (ROA)
-12.06%-12.06%-12.53%-11.80%-9.44%-21.77%
Upgrade
Return on Capital Employed (ROCE)
-21.50%-21.50%-21.60%-25.50%-21.50%-38.60%
Upgrade
Earnings Yield
-14.41%-15.70%-16.80%-11.27%-13.21%-10.42%
Upgrade
FCF Yield
-4.41%-4.80%-21.36%-15.33%0.33%-5.79%
Upgrade
Buyback Yield / Dilution
-14.95%-14.95%-15.94%-1.69%-3.22%-9.64%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.